Official Title
Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib
Brief Summary

In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling its disease coronavirus-19 or COVID-19. The mortality of the virus has been reported around 2-10% and its causes because of the proinflammatory immune response generated on the host. The cytokines involved in the immune response to COVID-19 are IL-1, IL-2, IL4, IL-6, IL-10, IL-12, IL-13, IL-17, GCSF, MCSF, IP-10, MCP-1, MIP-1α, HGF, IFN-γ y TNF-α. Ruxolitinib is an inhibitor of JAK 1/2 which is responsable for multiple cellular signals including the proinflammatory IL-6. Ruxolitinib works as and immunomodulator decreasing the cytotoxic T lymphocytes and increasing the Treg cells. This study is intended to stop the disregulated immune response caused by COVID-19 that generates the pneumonia and subsequent severe acute respiratory syndrome.

Completed
COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2

Drug: Ruxolitinib Oral Tablet

Ruxolitinib 5 mg twice a day

Eligibility Criteria

Inclusion Criteria:

- Patients with diagnosed COVID-19 with confirmatory test

- Increase in work of breathing or presence of dyspnea

- Presence of lung changes associated with COVID pneumonia by chest imaging

- Informed consent

Exclusion Criteria:

- Pregnancy or breastfeeding

- Thrombocytopenia below 20,000 cells/mm3

- Neutropenia below 500 cels/mm3

- Known and active infection of HIV, Hepatitis C, Hepatitis B, Herpes Zoster or
Mycobacterium Tuberculosis

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Mexico
Locations

Grupo Cooperativo de Hemopatías Malignas
Huixquilucan, Estado De México, Mexico

Grupo Cooperativo de Hemopatías Malignas
NCT Number
MeSH Terms
COVID-19
Severe Acute Respiratory Syndrome
Syndrome